#VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19
1. All-cause mortality at 28 days was significantly higher in the usual care group compared to the casirivimab and imdevimab ...
Tag: IgG1 SARS-CoV-2
